Subscribe to our Newsletters !!
Although copying the blueprint is extremely comple
Biotech Fluidics offers a range of micro spargers
The recent rabies death of an 11 year old Canadian
Eppendorf is launching the new Centrifuge 5811 R,a
Generic medicines have become a cornerstone in hea
Tofu used to be associated with Asian cuisine, but
Dear Readers, Welcome to the latest issue of Micr
The company has received approval from the United States Food and Drug Administration (USFDA) to advertise its own Dimethyl Fumarate delayed-release capsules in the strengths of 120 mg and 240 mg, Lupin said in a statement.
The item is a generic version of Biogen Inc”s Tecfidera delayed-release capsules at the same strengths, it added.
The company hopes to launch the product shortly, the announcement said.
According to the IQVIA MAT June 2020 data, Dimethyl Fumarate delayed-release capsules had an annual sales of approximately USD 3,788 million in the US, Lupin said.
The capsules are suggested,”for the treatment of patients with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and lively secondary progressive disease, in adults,” it added.
PTI AKT RUJ RUJ
